Xylem (XYL) insider buying and selling
Every Table I transaction reported by directors and officers of S&P 500 companies on SEC Form 4 filings (2 business days to file): each row labeled with its official transaction code, nothing filtered out beforehand.
Open-market purchases (code P) are the rare signal, in green; sales (code S) are common and often pre-scheduled (10b5-1). Table II (derivatives) is not included: its prices are exercise prices, not market values. Guide: insider buying.
| Date | Ticker | Insider | Role | Shares | Price | Amount | % of stake | Type / filing |
|---|
Download these transactions as CSV No account, no sign-up. The data is public: it comes from SEC Form 4 filings.
Xylem Inc. (XYL) insider buying and selling: 1 purchase, 4 sales
58 Form 4 Table I transactions filed with the SEC by Xylem Inc. insiders between 2025-09-03 and 2026-10-01 (15-month history): 1 open-market purchase and 4 sales, plus 53 transactions under other Form 4 codes, broken down one by one below. The largest open-market trade is a sale of $1.6M by Toussaint Claudia S on 2025-10-30.
Xylem insider buying and selling over the last 12 months
Between Oct 21, 2025 and Oct 20, 2026, Xylem insiders filed 1 purchase worth $141k and 3 sales worth $2.3M on the open market. The net balance is on the sell side: $2.2M more sold than bought.
The biggest buyer was Peribere Jerome A (Director): $141k in 1 purchase, the only buyer. The biggest seller was Toussaint Claudia S (EVP, CPSO): $1.6M in 1 sale, out of 3 different sellers.
The largest trade of the period was a sale of $1.6M on Oct 30, 2025, by Toussaint Claudia S (EVP, CPSO). Form 4 on sec.gov (0001524472-25-000050).
None of the 3 sales carries the 10b5-1 plan flag on the Form 4 (sales scheduled months ahead).
The last three months show 0 purchases and 0 sales, against 1 and 1 in the three before. The latest purchase is from May 4, 2026; the latest sale from May 7, 2026.
Against its sector (Industrials, 75 companies with an insider page on this site), over the same dates the median is 8 sales and 0 purchases on the open market. Xylem has more sales than 11 of the other 74, ranks 64 of 75 by net dollars sold, and 28 of the 75 have at least one purchase, Xylem included.
The 20 most important trades
The only open-market purchase first, then the rest, each type from largest to smallest. The full history is in the tool above, already searched.
See all 58 XYL trades in the full history →
| Trade date | Filed | Insider | Role | Amount | Code | Filing |
|---|---|---|---|---|---|---|
| 2026-05-04 | 2026-05-04 | Peribere Jerome A | Director | $141k | P — Open-market purchase Indirect holding, through: Jerome A Peribere 2016 Revocable TR | SEC |
| 2025-10-30 | 2025-10-31 | Toussaint Claudia S | EVP, CPSO | $1.6M | S — Open-market sale Indirect holding, through: by Claudia S. Toussaint Revocable Trust 2 Form 4 footnotesF1 Reflects the sale of shares of common stock from the Claudia S. Toussaint Revocable Trust of which the reporting person is trustee. The reporting person and members of her immediate family are the sole beneficiaries of the trust. F2 This price represents the weighted average price per share of common stock (each, a "Share") of Xylem Inc. (the "Issuer"). 10,421 Shares were executed at a range of prices from $152.51 to $152.98. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares sold at each price. | SEC |
| 2026-05-07 | 2026-05-08 | Mcshane Geri-Michelle | SVP, CAO | $501k | S — Open-market saleForm 4 footnoteF1 This price represents the weighted average price per share of common stock (each, a "Share") of Xylem Inc. (the "Issuer"). 4,269 Shares were executed at a range of prices from $117.42 to $118.17. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares sold at each price. | SEC |
| 2025-11-04 | 2025-11-05 | Harker Victoria D | Director | $252k | S — Open-market saleForm 4 footnoteF1 This price represents the weighted average price per share of common stock (each, a "Share") of Xylem Inc. (the "Issuer"). 1,700 Shares were executed at a range of prices from $148.135 to $148.135. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares sold at each price. | SEC |
| 2025-09-05 | 2025-09-05 | Mcshane Geri-Michelle | VP, CAO | $140k | S — Open-market saleForm 4 footnoteF1 This price represents the weighted average price per share of common stock (each, a "Share") of Xylem Inc. (the "Issuer"). 1,000 Shares were executed at a range of prices from $139.96 to $139.98. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares sold at each price. | SEC |
| 2026-03-01 | 2026-03-03 | Pine Matthew Francis | Pres. & CEO | $1.9M | A — Grant or award5 Form 4 footnotesF1 Reflects the acquisition of 5,243 shares of common stock upon vesting of performance-based stock units granted on March 1, 2023 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to Total Shareholder Return. F2 Includes additional shares due to dividend reinvestment. F3 Reflects the acquisition of 4,328 shares of common stock upon vesting of performance-based stock units granted on March 1, 2023 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to Adjusted EBITDA. F4 Reflects the acquisition of 2,943 shares of common stock upon vesting of performance-based stock units granted on March 1, 2023 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to Revenue. F5 Reflects the acquisition of 2,152 shares of common stock upon vesting of performance-based stock units granted on March 1, 2021 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to ESG performance. | SEC |
| 2026-03-01 | 2026-03-03 | Grogan William K | EVP & Chief Financial Officer | $1.7M | A — Grant or award4 Form 4 footnotesF1 Reflects the acquisition of 5,551 shares of common stock upon vesting of performance-based stock units granted on March 1, 2023 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to Total Shareholder Return. F2 Includes additional shares due to dividend reinvestment. F3 Reflects the acquisition of 4,583 shares of common stock upon vesting of performance-based stock units granted on March 1, 2023 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to Adjusted EBITDA. F4 Reflects the acquisition of 3,117 shares of common stock upon vesting of performance-based stock units granted on March 1, 2023 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to Revenue. | SEC |
| 2026-03-01 | 2026-03-03 | Yarkadas Hayati | EVP & President, WI | $1.6M | A — Grant or award5 Form 4 footnotesF1 Reflects the acquisition of 4,456 shares of common stock upon vesting of performance-based stock units granted on March 1, 2023 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to Total Shareholder Return. F2 Includes additional shares due to dividend reinvestment. F3 Reflects the acquisition of 3,679 shares of common stock upon vesting of performance-based stock units granted on March 1, 2023 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to Adjusted EBITDA. F4 Reflects the acquisition of 2,501 shares of common stock upon vesting of performance-based stock units granted on March 1, 2023 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to Revenue. F5 Reflects the acquisition of 1,761 shares of common stock upon vesting of performance-based stock units granted on March 1, 2021 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to ESG performance. | SEC |
| 2026-03-02 | 2026-03-03 | Pine Matthew Francis | Pres. & CEO | $1.0M | F — Tax withholding (shares surrendered for taxes)3 Form 4 footnotesF7 Reflects the withholding of shares of common stock to pay the tax liability incident to the vesting of performance-based stock units granted on March 1, 2023 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February, 24 2016). F8 Reflects the withholding of shares of common stock to pay the tax liability incident to the vesting of ESG performance-based stock units granted on March 1, 2021 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February, 24, 2016). F9 Reflects the withholding of shares of common stock to pay the tax liability incident to the vesting of restricted stock units granted on March 1, 2023 (649) and March 1, 2024 (1,667) under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016). | SEC |
| 2026-03-01 | 2026-03-03 | Toussaint Claudia S | EVP, CPSO | $954k | A — Grant or award4 Form 4 footnotesF1 Reflects the acquisition of 2,360 shares of common stock upon vesting of performance-based stock units granted on March 1, 2023 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to Total Shareholder Return. F2 Reflects the acquisition of 1,948 shares of common stock upon vesting of performance-based stock units granted on March 1, 2023 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to Adjusted EBITDA. F3 Reflects the acquisition of 1,324 shares of common stock upon vesting of performance-based stock units granted on March 1, 2023 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to Revenue. F4 Reflects the acquisition of 1,761 shares of common stock upon vesting of performance-based stock units granted on March 1, 2021 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to ESG performance. | SEC |
| 2026-03-02 | 2026-03-03 | Grogan William K | EVP & Chief Financial Officer | $834k | F — Tax withholding (shares surrendered for taxes)2 Form 4 footnotesF6 Reflects the withholding of shares of common stock to pay the tax liability incident to the vesting of performance-based stock units granted on March 1, 2023 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February, 24 2016). F7 Reflects the withholding of shares of common stock to pay the tax liability incident to the vesting of restricted stock units granted on March 1, 2024 (578) under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016). | SEC |
| 2026-03-01 | 2026-03-03 | Mcgann Michael J. | EVP & President, MCS | $668k | A — Grant or award5 Form 4 footnotesF1 Reflects the acquisition of 1,966 shares of common stock upon vesting of performance-based stock units granted on March 1, 2023 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to Total Shareholder Return. F2 Includes additional shares due to dividend reinvestment. F3 Reflects the acquisition of 1,622 shares of common stock upon vesting of performance-based stock units granted on March 1, 2023 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to Adjusted EBITDA. F4 Reflects the acquisition of 1,103 shares of common stock upon vesting of performance-based stock units granted on March 1, 2023 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to Revenue. F5 Reflects the acquisition of 489 shares of common stock upon vesting of performance-based stock units granted on March 1, 2021 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to ESG performance. | SEC |
| 2025-09-18 | 2025-09-18 | Grogan William K | SVP & Chief Financial Officer | $605k | F — Tax withholding (shares surrendered for taxes)2 Form 4 footnotesF1 Reflects the withholding of shares of common stock to pay the tax liability incident to the vesting of restricted stock units granted on September 18, 2023 (4,254) under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016). F2 Includes additional shares due to dividend reinvestment. | SEC |
| 2026-03-02 | 2026-03-03 | Toussaint Claudia S | EVP, CPSO | $513k | F — Tax withholding (shares surrendered for taxes)3 Form 4 footnotesF6 Reflects the withholding of shares of common stock to pay the tax liability incident to the vesting of performance-based stock units granted on March 1, 2023 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February, 24 2016). F7 Reflects the withholding of shares of common stock to pay the tax liability incident to the vesting of ESG performance-based stock units granted on March 1, 2021 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February, 24, 2016). F8 Reflects the withholding of shares of common stock to pay the tax liability incident to the vesting of restricted stock units granted on March 1, 2023 (336) and March 1, 2024 (266) under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016). | SEC |
| 2026-03-01 | 2026-03-03 | Cho Albert | EVP, Strategy | $479k | A — Grant or award5 Form 4 footnotesF1 Reflects the acquisition of 1,311 shares of common stock upon vesting of performance-based stock units granted on March 1, 2023 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to Total Shareholder Return. F2 Includes additional shares due to dividend reinvestment. F3 Reflects the acquisition of 1,082 shares of common stock upon vesting of performance-based stock units granted on March 1, 2023 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to Adjusted EBITDA. F4 Reflects the acquisition of 735 shares of common stock upon vesting of performance-based stock units granted on March 1, 2023 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to Revenue. F5 Reflects the acquisition of 587 shares of common stock upon vesting of performance-based stock units granted on March 1, 2021 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to ESG performance. | SEC |
| 2026-03-02 | 2026-03-03 | Mcgann Michael J. | EVP & President, MCS | $361k | F — Tax withholding (shares surrendered for taxes)3 Form 4 footnotesF7 Reflects the withholding of shares of common stock to pay the tax liability incident to the vesting of performance-based stock units granted on March 1, 2023 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February, 24 2016). F8 Reflects the withholding of shares of common stock to pay the tax liability incident to the vesting of ESG performance-based stock units granted on March 1, 2021 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February, 24, 2016). F9 Reflects the withholding of shares of common stock to pay the tax liability incident to the vesting of restricted stock units granted on March 1, 2023 (269) and March 1, 2024 (241) under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016). | SEC |
| 2026-03-02 | 2026-03-03 | Cho Albert | EVP, Strategy | $294k | F — Tax withholding (shares surrendered for taxes)3 Form 4 footnotesF7 Reflects the withholding of shares of common stock to pay the tax liability incident to the vesting of performance-based stock units granted on March 1, 2023 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February, 24 2016). F8 Reflects the withholding of shares of common stock to pay the tax liability incident to the vesting of ESG performance-based stock units granted on March 1, 2021 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February, 24, 2016). F9 Reflects the withholding of shares of common stock to pay the tax liability incident to the vesting of restricted stock units granted on March 1, 2023 (207) and March 1, 2024 (164) under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016). | SEC |
| 2026-05-14 | 2026-05-15 | Friel Robert F | Director | $290k | A — Grant or award2 Form 4 footnotesF1 Reflects an award of restricted stock units pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016) that are scheduled to vest in full on the trading day prior to the 2027 Annual Meeting of Shareholders. The Reporting Person has elected to defer the settlement of the RSU Award until Separation from Service. F2 Includes additional shares due to dividend reinvestment. | SEC |
| 2026-03-01 | 2026-03-03 | Mcshane Geri-Michelle | SVP, CAO | $285k | A — Grant or award4 Form 4 footnotesF1 Reflects the acquisition of 721 shares of common stock upon vesting of performance-based stock units granted on March 1, 2023 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to Total Shareholder Return. F2 Reflects the acquisition of 595 shares of common stock upon vesting of performance-based stock units granted on March 1, 2023 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to Adjusted EBITDA. F3 Reflects the acquisition of 405 shares of common stock upon vesting of performance-based stock units granted on March 1, 2023 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to Revenue. F4 Reflects the acquisition of 489 shares of common stock upon vesting of performance-based stock units granted on March 1, 2021 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to ESG performance. | SEC |
| 2026-05-07 | 2026-05-08 | Mcshane Geri-Michelle | SVP, CAO | $273k | M — Option exercise | SEC |
The period balance: money in, money out
Across the Form 4 filings submitted between Sep 3, 2025 and Oct 1, 2026, Xylem Inc. open-market activity adds up to 1 purchase worth $141k and 4 sales worth $2.5M. The net balance is $2.3M on the sell side.
Only codes P and S count, where an insider puts in or takes out their own money. A selling balance like Xylem Inc.'s is the norm in the S&P 500, where much of the pay comes as stock. It is not a recommendation to buy or sell: it is what was filed.
Every transaction, code by code
| Code | What it means | Trades | Reported amount |
|---|---|---|---|
| A | Grant or award | 30 | $9.5M |
| F | Tax withholding (shares surrendered for taxes) | 22 | $4.8M |
| S | Open-market sale | 4 | $2.5M |
| M | Option exercise | 1 | $273k |
| P | Open-market purchase | 1 | $141k |
| Total | Everything filed in the period | 58 | $17.3M |
13 of the 58 rows carry no usable amount on the Form 4: they count as trades and add $0. The code labels come from the SEC index.
Who has traded
Over the 15 months of history, 21 distinct people or entities have filed Xylem Inc. transactions: 1 bought on the open market and 3 sold. Counted by CIK, the fixed number the SEC gives each filer, and not by name, which each filer types their own way.
| Filer | Role | Transactions | Bought (count) | Sold (count) | Last filed |
|---|---|---|---|---|---|
| Toussaint Claudia S | EVP, CP&SO | 5 | — | $1.6M (1) | 2026-03-06 |
| Mcshane Geri-Michelle | SVP, CAO | 8 | — | $641k (2) | 2026-10-01 |
| Harker Victoria D | Director | 2 | — | $252k (1) | 2026-05-15 |
| Peribere Jerome A | Director | 2 | $141k (1) | — | 2026-05-15 |
| Aulick Rodney | EVP & President, WSS | 5 | — | — | 2026-03-06 |
| Grogan William K | EVP & Chief Financial Officer | 5 | — | — | 2026-03-06 |
| Cho Albert | EVP, Strategy | 4 | — | — | 2026-03-06 |
| Mcgann Michael J. | EVP & President, MCS | 4 | — | — | 2026-03-06 |
Shown here are the 8 who moved the most money, out of 21. The rest are in the full history, one link above. The name links to all their trades, in any company. "Transactions" counts any code; the money, open market only. Role: from their latest filing.
Month by month
By the month the trade was executed, not the month it was filed; months with no trades show zero. The busiest month was May 2026: 1 purchase and 1 sale, worth $643k. 11 of the 15 months have none.
| Month | Purchases | Amount | Sales | Amount |
|---|---|---|---|---|
| Aug 2025 | 0 | $0 | 0 | $0 |
| Sep 2025 | 0 | $0 | 1 | $140k |
| Oct 2025 | 0 | $0 | 1 | $1.6M |
| Nov 2025 | 0 | $0 | 1 | $252k |
| Dec 2025 | 0 | $0 | 0 | $0 |
| Jan 2026 | 0 | $0 | 0 | $0 |
| Feb 2026 | 0 | $0 | 0 | $0 |
| Mar 2026 | 0 | $0 | 0 | $0 |
| Apr 2026 | 0 | $0 | 0 | $0 |
| May 2026 | 1 | $141k | 1 | $501k |
| Jun 2026 | 0 | $0 | 0 | $0 |
| Jul 2026 | 0 | $0 | 0 | $0 |
| Aug 2026 | 0 | $0 | 0 | $0 |
| Sep 2026 | 0 | $0 | 0 | $0 |
| Oct 2026 | 0 | $0 | 0 | $0 |
The last month may be partial: a Form 4 is filed up to two business days later. The table does not say whether the pattern is good or bad; it says when it happened.
Xylem Inc. (XYL) analysis page →
Other Industrials companies with insider trades
All 500 are listed in the section index →
Which insiders are buying their own company stock →
How to read this data
None of the 4 sales in the table is flagged as scheduled (10b5-1 plan), the kind signed months ahead and executed automatically. Xylem's single open-market purchase (code P) is the rare signal: insiders are already paid in stock, so buying more means putting in their own money. The latest filing is from Oct 1, 2026, and a Form 4 arrives up to two business days after the trade.
18 of the 20 rows in the table carry footnotes from the Form 4 itself, folded into the code column and copied verbatim; a row with no footnote means the filing has none.
Guide: Insider buying · all guides
What is behind these trades
The concepts on this page, explained from scratch in the Academy. Free, no account.
- What the efficiency hypothesis says and what it does NOT sayIf an insider's purchase is public and anyone can read it, is there any information left in it? That is the exact question that brings people here.
- Who really moves the market: the types of investorWho sits on the other side of each order, and where a company's own insiders fit among them.
- Supply, demand and price: why it rises and falls constantlyHow a piece of news ends up inside the price, and why the reaction to a filed sale is rarely the one you would expect.
Source: SEC EDGAR Form 4. This is a list of public facts, not financial advice or a recommendation to buy or sell.